argenx SE (ARGX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Amsterdam, オランダ. 現CEOは Timothy Van Hauwermeiren.
ARGX を有する IPO日 2017-05-18, 1,599 名の正社員, に上場 NASDAQ Global Select, 時価総額 $51.26B.
Argenx SE is a biotechnology company headquartered in Amsterdam, Netherlands, focused on developing innovative therapies for autoimmune diseases across the United States, Europe, Japan, China, and other global markets. The company's lead product, efgartigimod, targets multiple autoimmune conditions including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris, with a pipeline of additional candidates such as empasiprubart and ARGX-119 addressing conditions like motor neuropathy and amyotrophic lateral sclerosis. Argenx has established strategic partnerships with major pharmaceutical companies including AbbVie, Zai Lab, and LEO Pharma, along with collaborations with leading academic institutions and biotech firms to advance its research and development efforts. The company leverages proprietary platforms and technologies, including its SIMPLE ANTIBODY technology, to discover and develop novel therapeutic antibodies with applications in immunology and oncology.
